• Je něco špatně v tomto záznamu ?

Immunoprotective neo-glycoproteins: Chemoenzymatic synthesis of multivalent glycomimetics for inhibition of cancer-related galectin-3

V. Heine, M. Hovorková, M. Vlachová, M. Filipová, L. Bumba, O. Janoušková, M. Hubálek, J. Cvačka, L. Petrásková, H. Pelantová, V. Křen, L. Elling, P. Bojarová

. 2021 ; 220 (-) : 113500. [pub] 20210427

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025156

Galectin-3 plays a crucial role in cancerogenesis; its targeting is a prospective pathway in cancer diagnostics and therapy. Multivalent presentation of glycans was shown to strongly increase the affinity of glycoconjugates to galectin-3. Further strengthening of interaction with galectin-3 may be accomplished using artificial glycomimetics with apt aryl substitutions. We established a new, as yet undescribed chemoenzymatic method to produce selective C-3-substituted N,N'-diacetyllactosamine glycomimetics and coupled them to human serum albumin. From a library of enzymes, only β-N-acetylhexosaminidase from Talaromyces flavus was able to efficiently synthesize the C-3-propargylated disaccharide. Various aryl residues were attached to the functionalized N,N'-diacetyllactosamine via click chemistry to assess the impact of the aromatic substitution. In ELISA-type assays with galectin-3, free glycomimetics exhibited up to 43-fold stronger inhibitory potency to Gal-3 than the lactose standard. Coupling to human serum albumin afforded multivalent neo-glycoproteins with up to 4209-fold increased inhibitory potency per glycan compared to the monovalent lactose standard. Surface plasmon resonance brought further information on the kinetics of galectin-3 inhibition. The potential of prepared neo-glycoproteins to target galectin-3 was demonstrated on colorectal adenocarcinoma DLD-1 cells. We investigated the uptake of neo-glycoproteins into cells and observed limited non-specific transport into the cytoplasm. Therefore, neo-glycoproteins primarily act as efficient scavengers of exogenous galectin-3 of cancer cells, inhibiting its interaction with the cell surface, and protecting T-lymphocytes against galectin-3-induced apoptosis. The present neo-glycoproteins combine the advantage of a straightforward synthesis, selectivity, non-toxicity, and high efficiency for targeting exogenous galectin-3, with possible application in the immunomodulatory treatment of galectin-3-overexpressing cancers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025156
003      
CZ-PrNML
005      
20211026134055.0
007      
ta
008      
211013s2021 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2021.113500 $2 doi
035    __
$a (PubMed)33962190
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Heine, Viktoria $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic; Institute of Biotechnology and Helmholtz Institute for Biomedical Engineering, RWTH Aachen, Pauwelstr. 20, D-52079 Aachen, Germany
245    10
$a Immunoprotective neo-glycoproteins: Chemoenzymatic synthesis of multivalent glycomimetics for inhibition of cancer-related galectin-3 / $c V. Heine, M. Hovorková, M. Vlachová, M. Filipová, L. Bumba, O. Janoušková, M. Hubálek, J. Cvačka, L. Petrásková, H. Pelantová, V. Křen, L. Elling, P. Bojarová
520    9_
$a Galectin-3 plays a crucial role in cancerogenesis; its targeting is a prospective pathway in cancer diagnostics and therapy. Multivalent presentation of glycans was shown to strongly increase the affinity of glycoconjugates to galectin-3. Further strengthening of interaction with galectin-3 may be accomplished using artificial glycomimetics with apt aryl substitutions. We established a new, as yet undescribed chemoenzymatic method to produce selective C-3-substituted N,N'-diacetyllactosamine glycomimetics and coupled them to human serum albumin. From a library of enzymes, only β-N-acetylhexosaminidase from Talaromyces flavus was able to efficiently synthesize the C-3-propargylated disaccharide. Various aryl residues were attached to the functionalized N,N'-diacetyllactosamine via click chemistry to assess the impact of the aromatic substitution. In ELISA-type assays with galectin-3, free glycomimetics exhibited up to 43-fold stronger inhibitory potency to Gal-3 than the lactose standard. Coupling to human serum albumin afforded multivalent neo-glycoproteins with up to 4209-fold increased inhibitory potency per glycan compared to the monovalent lactose standard. Surface plasmon resonance brought further information on the kinetics of galectin-3 inhibition. The potential of prepared neo-glycoproteins to target galectin-3 was demonstrated on colorectal adenocarcinoma DLD-1 cells. We investigated the uptake of neo-glycoproteins into cells and observed limited non-specific transport into the cytoplasm. Therefore, neo-glycoproteins primarily act as efficient scavengers of exogenous galectin-3 of cancer cells, inhibiting its interaction with the cell surface, and protecting T-lymphocytes against galectin-3-induced apoptosis. The present neo-glycoproteins combine the advantage of a straightforward synthesis, selectivity, non-toxicity, and high efficiency for targeting exogenous galectin-3, with possible application in the immunomodulatory treatment of galectin-3-overexpressing cancers.
650    _2
$a biomimetické materiály $x chemická syntéza $x chemie $x farmakologie $7 D040761
650    _2
$a krevní proteiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D001798
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a galektiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D037161
650    _2
$a glykoproteiny $x chemie $x metabolismus $7 D006023
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a molekulární struktura $7 D015394
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hovorková, Michaela $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic; Department of Genetics and Microbiology, Faculty of Science, Charles University, Viničná 5, CZ-12843, Prague 2, Czech Republic
700    1_
$a Vlachová, Miluše $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
700    1_
$a Filipová, Marcela $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského Nám. 2, CZ-16206 Prague 6, Czech Republic
700    1_
$a Bumba, Ladislav $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
700    1_
$a Janoušková, Olga $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského Nám. 2, CZ-16206 Prague 6, Czech Republic
700    1_
$a Hubálek, Martin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Náměstí 2, CZ-16610 Prague 6, Czech Republic
700    1_
$a Cvačka, Josef $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Náměstí 2, CZ-16610 Prague 6, Czech Republic
700    1_
$a Petrásková, Lucie $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
700    1_
$a Pelantová, Helena $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
700    1_
$a Křen, Vladimír $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
700    1_
$a Elling, Lothar $u Institute of Biotechnology and Helmholtz Institute for Biomedical Engineering, RWTH Aachen, Pauwelstr. 20, D-52079 Aachen, Germany
700    1_
$a Bojarová, Pavla $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic. Electronic address: bojarova@biomed.cas.cz
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 220, č. - (2021), s. 113500
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33962190 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134101 $b ABA008
999    __
$a ok $b bmc $g 1714277 $s 1145663
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 220 $c - $d 113500 $e 20210427 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...